SBIR Phase I: Progeny Analysis Of A Chimera-Free Hypoallergenic Peanut

这个小企业创新研究（SBIR）第一阶段项目的更广泛的影响/商业潜力是开发一种低过敏性花生（HAP）品种，预计通过预防过敏相关的死亡来挽救人类生命，减少花生过敏的发生率，并为那些对花生敏感的人及其家人，大家庭，朋友，学校和餐馆增加安全，舒适和安心。 HAP还可以减少和/或消除由花生过敏事件引起的机构诉讼的数量，并且减少和/或消除由于花生污染而导致的昂贵的食品召回的数量。减少过敏原可能会挽回花生市场遭受的损失，提高美国在国际花生市场上的竞争优势，并由于餐馆、航空公司等市场的增加而使销售额增加15%至20%。食物过敏每年花费250亿美元，花生是主要贡献者。HAP将为花生过敏提供一个重要的解决方案，并有可能降低食物过敏的总成本。 这个SBIR第一阶段项目的智力价值是生产一种低过敏性花生的商业原型，作为全国范围内花生过敏严重健康问题的解决方案。在以前的工作中，HAP是通过同时沉默编码三种最有效的花生过敏原Ara h 1、Ara h 2和Ara h 3的基因而开发的。HAP的致敏效力降低2至85倍，并且HAP性状在田间试验中传递给连续几代。然而，一些转基因花生被发现是嵌合的，并产生具有可变水平的致敏效力的非同质种子群体。为了解决这一问题，使用重复体细胞胚发生组织来产生第一代无嵌合体的HAP（T0植物）。在该I期项目期间，将使用Southern印迹和定量PCR分析后代T1植物以确认植物的无嵌合体状态。将进行逆转录酶定量PCR、蛋白质印迹、夹心ELISA和免疫帽试验，以确认子代T2种子的群体是同质的，并且具有不可检测水平的靶向过敏原。该奖项反映了NSF的法定使命，并已被认为值得通过使用基金会的知识价值和更广泛的影响审查标准进行评估的支持。

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop a hypo allergenic peanut (HAP) variety, which is expected to save human lives by preventing allergy-related deaths, reduce the incidence of peanut allergy, and increase security, comfort and peace of mind for those individuals sensitive to peanuts and their families, extended families, friends, schools, and restaurants. HAP also may reduce and/or eliminate the number of institutional lawsuits resulting from peanut allergy events, and reduce and/or eliminate the number of costly food recalls due to peanut contaminations. Reducing allergens may gain back the loss endured by the peanut market, improve the U.S. competitive edge on the international peanut market, and increase sales by 15% to 20% due to an increase market by restaurants, airlines and more. Food allergies cost the US $25 billion annually and peanut is a major contributor. HAP will provide a significant solution to peanut allergy with the potential to reduce the overall cost of food allergy. The intellectual merit of this SBIR Phase I project is to produce a commercial prototype for a hypoallergenic peanut as a solution to the serious health concern nationwide for peanut allergy. In previous work, a HAP was developed by concomitant silencing of the genes coding for the three most potent peanut allergens Ara h 1, Ara h 2 and Ara h 3. The HAP was 2 to 85-fold reduced in allergenic potency, and the HAP trait was transmitted to several successive generations in field trials. However, some of the transgenic peanuts were found to be chimeric and to produce non-homogeneous population of seeds with variable levels of allergenic potency. To solve this problem, repetitive somatic embryogenic tissue was used to produce first generation chimera-free HAP (T0 plants). During this Phase I project, the progeny T1 plants will be analyzed using Southern blot and quantitative PCR to confirm the chimera-free status of the plants. Reverse transcriptase quantitative PCR, Western blot, sandwich ELISA and immunoCap assay will be performed to confirm the population of the progeny T2 seeds is homogenous and has undetectable levels of the targeted allergens. A commercial prototype variety for the hypoallergenic peanut will be identified and selected for further studies.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.